Skip to main content
padlock icon - secure page this page is secure

Treatment of Migraine in Canada With Naratriptan: A Cost-Effectiveness Analysis

Buy Article:

The full text article is temporarily unavailable.

We apologise for the inconvenience. Please try again later.

Objective.—To evaluate the cost-effectiveness of naratriptan for the treatment of migraine in Canada.

Background.—The substantial disability brought on by migraine, coupled with the high prevalence of this disorder, leads to substantial costs. Naratriptan is a newly developed triptan shown to be effective in the treatment of migraine.

Methods.—Monte Carlo modeling techniques were used to simulate the experience of Canadian migraineurs over the course of 1 year. Data from a multinational study comparing oral naratriptan 2.5 mg to customary therapies were used in the cost-effectiveness analysis.

Results.—Naratriptan leads to an annual reduction in symptom duration of 225 hours compared to customary therapy not including other triptans. Reductions in lost productivity yield savings of Can $390 (1998 Canadian dollars) relative to customary therapy, which exceed the increase in drug costs resulting in overall savings of Can $109 per year.

Conclusions.—The use of naratriptan in the treatment of migraine is an economically attractive option, leading to savings in overall costs. Increases in drug costs seem acceptable in light of reductions in symptom duration.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Canada; Monte Carlo model; cost-effectiveness; migraine; naratriptan

Document Type: Research Article

Publication date: May 1, 2001

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more